Please login to the form below

Not currently logged in
Email:
Password:

Mirna Therapeutics appoints new executive vice president

Miguel Barbosa willalso serve as chief scientific officer

Mirna Therapeutics has appointed Dr Miguel Barbosa as executive vice president and chief scientific officer.

Mirna Therapeutics is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics.

Barbosa joined the company with 20 years of biopharmaceutical research discovery experience and for the past decade has served in senior leadership roles at Johnson & Johnson subsidiaries.

Paul Lammers, Mirna's president and chief executive officer, said: “We are pleased to welcome Miguel to the role of chief scientific officer.

As a highly accomplished industry executive with a proven ability to lead top research and development programs, we are confident Miguel's expertise and strategic vision, particularly in emerging areas of science, will prove critical as we advance our pipeline of microRNA-based oncology therapeutics.”

30th October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...